Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Genmab AS a un objectif de cours consensus de $38.73, basé sur les évaluations des 14 analystes. Le plus élevé est de $48 attribué par BMO Capital le novembre 8, 2024, et le plus bas est de $27 attribué par Leerink Partners le février 13, 2025. Les 3 dernières évaluations d'analystes ont été publiées par HC Wainwright & Co., HC Wainwright & Co. et Guggenheim le octobre 15, 2025, octobre 2, 2025 et septembre 24, 2025. Avec un objectif de cours moyen de $41 entre HC Wainwright & Co., HC Wainwright & Co. et Guggenheim, il y a une variation implicite de 24.51% upside pour Genmab AS à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
HC Wainwright & Co.
Guggenheim
Guggenheim
Truist Securities
Leerink Partners
1calculé à partir des notes des analystes
Notes d'analystes pour Genmab
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/15/2025 | 21.47% | HC Wainwright & Co. | $40 → $40 | Reiterates | Buy → Buy | |||
10/02/2025 | 21.47% | HC Wainwright & Co. | $36 → $40 | Maintains | Buy | |||
09/24/2025 | 30.58% | Guggenheim | → $43 | Upgrade | Neutral → Buy | |||
09/23/2025 | 30.58% | Guggenheim | → $43 | Upgrade | Neutral → Buy | |||
08/15/2025 | 9.32% | HC Wainwright & Co. | $35 → $36 | Maintains | Buy | |||
07/08/2025 | 39.69% | Truist Securities | $45 → $46 | Maintains | Buy | |||
05/13/2025 | 6.29% | HC Wainwright & Co. | $37 → $35 | Maintains | Buy | |||
04/09/2025 | 12.36% | HC Wainwright & Co. | $50 → $37 | Reiterates | Buy → Buy | |||
03/11/2025 | 36.65% | Truist Securities | $50 → $45 | Maintains | Buy | |||
03/11/2025 | — | William Blair | — | Upgrade | Market Perform → Outperform | |||
02/13/2025 | -18.01% | Leerink Partners | → $27 | Upgrade | Market Perform → Outperform | |||
01/23/2025 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
01/08/2025 | 51.84% | HC Wainwright & Co. | $50 → $50 | Maintains | Buy | |||
11/08/2024 | 45.76% | BMO Capital | $46 → $48 | Reiterates | Outperform → Outperform | |||
10/16/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
09/20/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
09/16/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
09/13/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
09/11/2024 | -5.86% | Morgan Stanley | $31 → $31 | Maintains | Equal-Weight | |||
09/09/2024 | 51.84% | Truist Securities | $53 → $50 | Maintains | Buy | |||
09/04/2024 | -5.86% | Morgan Stanley | → $31 | Reinstates | → Equal-Weight | |||
08/27/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
08/20/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
08/20/2024 | — | JP Morgan | — | Downgrade | Overweight → Neutral | |||
08/09/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
08/06/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
08/01/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
07/18/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
07/15/2024 | — | RBC Capital | — | Upgrade | Sector Perform → Outperform | |||
06/27/2024 | 42.73% | BTIG | $46 → $47 | Maintains | Buy | |||
06/27/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
06/20/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
06/04/2024 | 60.95% | Truist Securities | $50 → $53 | Maintains | Buy | |||
06/03/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
05/20/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
05/03/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
04/30/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
04/04/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
03/27/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Maintains | Buy | |||
03/26/2024 | -2.82% | Morgan Stanley | $32 → $32 | Maintains | Underweight | |||
03/26/2024 | 51.84% | Truist Securities | $50 → $50 | Maintains | Buy | |||
03/06/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
02/23/2024 | 45.76% | BMO Capital | $46 → $48 | Upgrade | Market Perform → Outperform | |||
02/20/2024 | 51.84% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
02/20/2024 | 51.84% | Truist Securities | $54 → $50 | Reiterates | Buy → Buy | |||
01/29/2024 | 51.84% | HC Wainwright & Co. | $49 → $50 | Maintains | Buy | |||
11/28/2023 | 48.8% | HC Wainwright & Co. | → $49 | Reiterates | Buy → Buy | |||
11/20/2023 | 48.8% | HC Wainwright & Co. | → $49 | Reiterates | Buy → Buy | |||
11/09/2023 | -2.82% | Morgan Stanley | $33 → $32 | Maintains | Underweight | |||
11/08/2023 | 48.8% | HC Wainwright & Co. | $51 → $49 | Maintains | Buy | |||
10/18/2023 | 54.87% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy | |||
10/13/2023 | 39.69% | BTIG | $44 → $46 | Maintains | Buy | |||
09/26/2023 | 63.98% | Truist Securities | → $54 | Reiterates | Buy → Buy | |||
09/06/2023 | 63.98% | Truist Securities | → $54 | Reiterates | Buy → Buy | |||
09/05/2023 | 54.87% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy | |||
08/24/2023 | 33.62% | BTIG | → $44 | Initiates | → Buy | |||
08/15/2023 | 54.87% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy | |||
08/04/2023 | 0.21% | Morgan Stanley | $33 → $33 | Reiterates | Underweight → Underweight | |||
08/04/2023 | 54.87% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy | |||
08/01/2023 | 0.21% | Morgan Stanley | $33 → $33 | Reiterates | Underweight → Underweight | |||
07/31/2023 | 0.21% | Morgan Stanley | $33 → $33 | Reiterates | Underweight → Underweight | |||
07/31/2023 | 54.87% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy | |||
07/24/2023 | 0.21% | Morgan Stanley | $33 → $33 | Reiterates | Underweight → Underweight | |||
07/17/2023 | 0.21% | Morgan Stanley | $33 → $33 | Reiterates | Underweight → Underweight | |||
07/11/2023 | 63.98% | Truist Securities | → $54 | Reiterates | Buy → Buy | |||
06/28/2023 | 54.87% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy | |||
06/26/2023 | 0.21% | Morgan Stanley | $33 → $33 | Reiterates | Underweight → Underweight | |||
06/26/2023 | 54.87% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy | |||
06/20/2023 | 0.21% | Morgan Stanley | → $33 | Reiterates | → Underweight | |||
06/14/2023 | 54.87% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy | |||
06/12/2023 | 0.21% | Morgan Stanley | → $33 | Reiterates | → Underweight | |||
06/06/2023 | 54.87% | HC Wainwright & Co. | → $51 | Reiterates | Buy → Buy | |||
05/22/2023 | 54.87% | HC Wainwright & Co. | $47 → $51 | Maintains | Buy | |||
05/16/2023 | 42.73% | HC Wainwright & Co. | $46 → $47 | Maintains | Buy | |||
04/20/2023 | 39.69% | HC Wainwright & Co. | → $46 | Reiterates | → Buy | |||
03/02/2023 | 39.69% | HC Wainwright & Co. | $51 → $46 | Maintains | Buy | |||
03/01/2023 | 0.21% | Morgan Stanley | $34 → $33 | Maintains | Underweight | |||
02/23/2023 | 3.25% | Morgan Stanley | $35 → $34 | Maintains | Underweight | |||
02/06/2023 | 9.32% | SVB Leerink | — | $33 → $36 | Maintains | Market Perform | ||
01/24/2023 | 6.29% | Morgan Stanley | $34 → $35 | Maintains | Underweight | |||
11/14/2022 | — | William Blair | — | Initiates | → Market Perform | |||
11/14/2022 | 3.25% | Morgan Stanley | $31 → $34 | Maintains | Underweight | |||
11/10/2022 | 0.21% | SVB Leerink | $31 → $33 | Maintains | Market Perform |
FAQ
Quel est le cours indicatif de l'action Genmab (GMAB) ?
Le dernier objectif de prix pour Genmab (NASDAQ:GMAB) a été rapporté par HC Wainwright & Co. le octobre 15, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $40.00 s'attendant à ce que GMAB se rise dans les 12 prochains mois (un possible changement de 21.47% upside). 14 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Genmab (GMAB) ?
La dernière note d'analyste pour Genmab (NASDAQ:GMAB) a été fournie par HC Wainwright & Co., et Genmab réitéré leur note buy.
Quand a eu lieu la dernière mise à niveau pour Genmab (GMAB) ?
La dernière amélioration pour Genmab AS a eu lieu le septembre 24, 2025 lorsque Guggenheim a augmenté leur objectif de prix à $43. Guggenheim avait précédemment a neutral pour Genmab AS.
Quand a eu lieu la dernière dégradation pour Genmab (GMAB) ?
La dernière réduction pour Genmab AS a eu lieu le août 20, 2024 lorsque JP Morgan a changé leur objectif de prix de N/A à N/A pour Genmab AS.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Genmab (GMAB) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Genmab, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Genmab a été déposée le octobre 15, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 15, 2026.
La note d'analyste pour Genmab (GMAB) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Genmab (GMAB) était un réitéré avec un objectif de prix de $40.00 à $40.00. Le prix actuel de Genmab (GMAB) est de $32.93, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.